Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2NET 2Gynecologic 2Endocrine 2Sarcoma 1Other solid neoplasm 1Gastrointestinal 1CNS 1

Conditions

Small Cell Lung Carcinoma 45Lung Neoplasms 42Carcinoma, Non-Small-Cell Lung 38Colorectal Neoplasms 12Pancreatic Neoplasms 10Breast Neoplasms 6Stomach Neoplasms 5Ovarian Neoplasms 5Neoplasm Metastasis 5Triple Negative Breast Neoplasms 4Neoplasms 4Uterine Cervical Neoplasms 3Sarcoma 3Rectal Neoplasms 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Recurrence 2Neuroendocrine Tumors 2Kidney Neoplasms 2Extensive Stage Small Cell Lung Cancer 2Adenocarcinoma, Bronchiolo-Alveolar 2Adenocarcinoma of Lung 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1

Interventions

Nivolumab 3Cyclophosphamide 3pembrolizumab 2fludarabine phosphate 2fludarabine 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Irinotecan 2Fluorodeoxyglucose F18 2Everolimus 2Carboplatin 2tislelizumab 1taxane 1surufatinib 1romidepsin 1repotrectinib 1pralsetinib 1olaparib 1liposomal doxorubicin 1entrectinib 1cabozantinib 1atezolizumab 1alectinib 1aldesleukin 1Vinorelbine 1Temozolomide 1Specimen Handling 1RRx-001 1Quality of Life 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Irinotecan × Thoracic × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡